Investopedia: Cepheid Soaring

Molecular diagnostics company Cepheid (Nasdaq:CPHD) has long been one of my go-to names whenever I need a high-growth name that the Street did not quite fully understand and appreciate. The good news is that the stock has made my advice look good by more than tripling since the start of 2010. The bad news is that the stock has gone so far so fast that the company is simply going to have to become one of the MDx leaders to validate its current valuation. 

Another Great Quarter for Both New and Recurring Business  
Cepheid did everything it was supposed to do in the second quarter, and a little more besides. Revenue jumped 35% in the quarter as the company saw product revenue growth of 31%. This growth was fueled by an increase in systems revenue of 53% and reagent revenue of 40%, all of which more than offset the 25% decline in non-clinical revenue. Cepheid's international business is also doing well, growing more than twice the rate of the North American business this quarter. 


To read the full piece, click below:
http://stocks.investopedia.com/stock-analysis/2011/Cepheid-Soaring-CPHD-BIO-GPRO-BDX-LMNX0802.aspx